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Abstract
Background: In the Netherlands, 30% of subfertile women are overweight or obese, and at present there is no agreement on 
fertility care for them. Data from observational and small intervention studies suggest that reduction of weight will increase 
the chances of conception, decrease pregnancy complications and improve perinatal outcome, but this has not been 
confirmed in randomised controlled trials. This study will assess the cost and effects of a six-months structured lifestyle 
program aiming at weight reduction followed by conventional fertility care (intervention group) as compared to 
conventional fertility care only (control group) in overweight and obese subfertile women. We hypothesize that the 
intervention will decrease the need for fertility treatment, diminish overweight-related pregnancy complications, and will 
improve perinatal outcome.
Methods/Design: Multicenter randomised controlled trial in subfertile women (age 18-39 year) with a body mass index 
between 29 and 40 kg/m2. Exclusion criteria are azoospermia, use of donor semen, severe endometriosis, premature ovarian 
failure, endocrinopathies or pre-existent hypertensive disorders.
In the intervention group the aim is a weight loss of at least 5% to10% in a six-month period, to be achieved by the combination 
of a diet, increase of physical activity and behavioural modification. After six months, in case no conception has been achieved, 
these patients will start fertility treatment according to the Dutch fertility guidelines. In the control group treatment will be 
started according to Dutch fertility guidelines, independently of the patient's weight.
Outcome measures and analysis: The primary outcome measure is a healthy singleton born after at least 37 weeks of gestation 
after vaginal delivery. Secondary outcome parameters including pregnancy outcome and complications, percentage of women 
needing fertility treatment, clinical and ongoing pregnancy rates, body weight, quality of life and costs.
Data will be analysed according to the intention to treat principle, and cost-effectiveness analysis will be performed to 
compare the costs and health effects in the intervention and control group.
Discussion: The trial will provide evidence for costs and effects of a lifestyle intervention aiming at weight reduction in 
overweight and obese subfertile women and will offer guidance to clinicians for the treatment of these patients.
Trial registration: Dutch Trial Register NTR1530
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There is indisputable evidence for the adverse effects of
overweight and obesity on women's reproductive health.
Overweight and obesity affect reproductive capacity in
the general population [1] as well as in subfertile couples
[2]. Ovulatory subfertile women with a body mass index
(BMI) of 29 kg/m2 or higher have a 4% lower pregnancy
rate per kg/m2 increase per year, compared to ovulatory
subfertile women with a BMI below 29. In the Nether-
lands, approximately 30% of subfertile couples are over-
weight or obese. [3] Since childhood obesity is increasing,
most notably among girls, a significant increase in obesity
related subfertility can be anticipated in the future [4].
Overweight and obese women also have a lower live
birth rate after IVF and ICSI [5-13], especially when these
women are 36 years or younger [14]. A meta-analysis on
the effect of overweight and obesity in artificial reproduc-
tive technologies (ART) reported a lower chance of preg-
nancy following IVF (OR 0.71, 95% CI:0.620-0.81) and an
increased miscarriage rate (OR 1.3, 95% CI:1.06-
1.68)[15].
Furthermore, pregnancies in obese women are associ-
ated with an increased risk of complications during preg-
nancy and delivery [16,17], causing an increase in
maternal and neonatal morbidity and mortality [18,19].
There are more neonatal admissions [20] and five times
higher costs [21].
In subfertile women lifestyle intervention could
improve spontaneous conception chances and prevent
unnecessary fertility treatment as well as obstetric com-
plications. Observational and small intervention studies
show that modest weight loss is associated with restora-
tion of ovulation in anovulatory women and improves the
likelihood of a pregnancy [22-24]. Weight loss can be
achieved by lifestyle intervention programs incorporating
the combination of a healthy diet, increase of physical
activity and behavioural modification [25]. Weight loss
has been advised for the improvement of reproductive
function in overweight women, specifically with polycys-
tic ovary syndrome (PCOS) [26,27]. In PCOS, insulin
resistance and hyperinsulinism play a major role [28]. It
has been shown that in women with PCOS even a modest
weight loss improves this prediabetic state, and increases
the rate of ovulation and the likelihood of a spontaneous
achieved uncomplicated pregnancy [23,24,29,30]. How-
ever, the evidence of the effectiveness of weight reduction
is still limited due to a lack of large controlled studies, and
the effectiveness has not been established preceding ART.
At present, there are no evidence-based guidelines on
fertility treatment in overweight and obese subfertile
women. In the Netherlands, in some centers treatment is
withheld in case of female overweight, and cut off levels
for body mass index (BMI) differ among clinics. In other
fertility centres overweight or obese women are treated
irrespective of their BMI. The British Fertility Society
advises to abstain from fertility treatment in women with
a BMI over 35 kg/m2 [31] and to start lifestyle interven-
tion aiming on weight reduction, although there is not
enough convincing evidence that weight reduction even-
tually leads to more spontaneous achieved uncompli-
cated pregnancies. Recently, a debate is started in
literature whether or not restricting the access to fertility
treatment on the ground of female body mass index. [32-
35]
In view of the lack of convincing evidence from large
intervention studies and the large practice variation in
many countries, we designed a randomized controlled
trial in overweight and obese subfertile women. In this
trial, we will compare the costs and effects of a six-
months structured lifestyle program followed by conven-
tional fertility care as opposed to immediate conventional
fertility care. We hypothesize that weight reduction
improves spontaneous and treatment-related pregnancy
chances, decreases overweight-related pregnancy com-
plications and improves perinatal outcome.
Methods
Study design
This study is a multicenter randomised controlled trial in
the Netherlands and inclusion started in July, 2009.
Inclusion criteria
Subfertile women between 18 and 39 years who have a
BMI between 29 kg/m2 and 40 kg/m2 are included. Sub-
fertility is defined as failure to conceive within 12 months
of unprotected intercourse in case of an ovulatory cycle,
or in case of chronic anovulation due to WHO class I or
II.
Exclusion criteria
Couples suffering from azoospermia or using donor
semen, women with endometriosis AFS class III or IV,
chronic anovulation WHO class III (premature ovarian
failure) or endocrinopathies (such as Cushing syndrome,
adrenal hyperplasia and diabetes type I) will not be eligi-
ble for the study. Women with untreated pre-existent
hypertension or with pregnancy induced hypertension,
preeclampsia, eclampsia or HELLP syndrome in a previ-
ous pregnancy are also excluded. Patients who are unable
to understand Dutch or to give informed consent will not
be asked to participate in the study.
Study management
All couples participating in the study will undergo a basic
fertility work-up including a semen-analysis, monitoring
of the cycle to assess ovulation and evaluation of tubal
patency. After the work-up has been completed a progno-
sis for treatment independent pregnancy will be calcu-
lated using the Hunault model [36], followed by a
management proposal for the individual couple.
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research nurse for counselling and randomisation. The
research nurse will not coach the patients during the life-
style program.
Written informed consent is obtained before randomis-
ation. Eligible women not willing to participate are regis-
tered as such.
Randomisation
Randomisation is performed by a web-based randomisa-
tion program at a central randomisation center. Ran-
domisation will be stratified according to participating
center and ovulatory status.
Intervention
1a. The intervention arm
In the intervention arm, patients will participate in six-
months during structured lifestyle program aiming at a
weight loss of at least 5-10% of the original body weight.
Nurses, dieticians or nurse practitioners who are trained
prior to the study (intervention nurses) will guide and
support them.
In the structured lifestyle program practice variation is
minimized by using a structured software program, that
has been evaluated previously [37].
As the combination of a dietary therapy, increased
physical activity and an individualized behavioural modi-
fication plan leads to maximal weight loss and mainte-
nance of weight loss[25,38,39] the lifestyle program
targets at these three interventions:
1. Changing the dietary pattern
Women will be advised to adapt their dietary pattern and
sustain a healthy diet with a caloric reduction of approxi-
mately 600kcal compared to their previous caloric intake
(but not below 1200 kcal/day).
Self-monitoring is an essential tool to improve compli-
ance during a lifestyle program. This will be implemented
by using a web-based food diary http://www.voeding-
scentrum.nl, which gives feedback on food and caloric
intake on a daily basis. Patients will be trained to use this
device and the intervention nurse and the patient will
together evaluate the daily caloric intake.
2. Stimulating physical activity of moderate intensity
Physical activity is necessary in order to obtain weight
loss and increase the effect of dietary changes [25,38].
Physical exercise of moderate intensity (60-85% of maxi-
mum heart rate frequency) is advised during two to three
times a week for at least 30 minutes. To increase physical
activity in daily life, a pedometer (PAM; step counter) will
be used aiming at 10.000 steps per day. To establish self-
monitoring, a diary will be kept on these physical activi-
ties.
3. Changing behaviour
The motivation to change physical activity is monitored
during the program by the PACE (Physician-based
Assessment and Counseling for Exercise) score [40]
which is part of the structured software program. This
score measures the stages of change: precontemplation
(not intending to change behaviour), contemplation (con-
sidering changing behaviour), preparation (making small
changes in behaviour), action (actively engaging in behav-
iour change) and maintenance (sustaining the behaviour
change over time). These stages are assessed at baseline,
after 12 weeks and after 24 weeks of randomisation.
Motivational counselling is individualized accordingly.
Changing behaviour is aimed for by motivational coun-
selling which is directed at:
- Awareness of actual lifestyle leading to overweight or
obesity.
- Counselling healthy lifestyle measures: the effect of
healthy lifestyle in relation to subfertility and spontane-
ous and treatment dependent pregnancy chances, preg-
nancy complications and perinatal outcome.
- Formulating individualized goals embedded in a
"patient contract". During the intervention individual
goals will be evaluated, feedback will be given and goals
will be adapted if necessary.
The lifestyle program consists of four sessions in the
first three months and two additional sessions in the last
three months. Four consultations by telephone or by e-
mail are scheduled in between these sessions (Table 1)
1b. Start of fertility treatment in the intervention group
As soon as patients in the intervention arm have finished
their six-month lifestyle program, or have met their target
weight reduction of 5-10% or when their BMI has
decreased below 29 kg/m2 , conventional fertility treat-
ment will be started according to their individual progno-
sis based on the Hunault model [36]. If the estimated
chance of spontaneous conception in ovulatory women is
less than 30% in the forthcoming year, or when the couple
has been subfertile for more than 3 years, fertility treat-
ment is offered according to the guidelines of the Dutch
Society of Obstetrics and Gynaecology (NVOG). Fertility
treatment can either be IUI, IVF or ICSI, whatever is indi-
cated according to the Dutch guidelines. When the
Hunault model shows a prognosis of more than 30%
pregnancy chance in the forthcoming year and patients
are less than three years subfertile, expectant manage-
ment will be proposed. In case of chronic anovulation,
ovulation induction will be started using clomiphene or
gonadotropins (Figure 1).
2. The control arm
In the control arm, independently of the patient's weight,
conventional fertility treatment will be started if the indi-
vidual prognosis based on the Hunault model [36] is less
than 30% chance of conception within the next year or
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Week Consultation
Outpatient, telephone or e-mail
Counseling subject lifestyle program Duration 
(minutes)
0 Randomisation Baseline assessment1,2 and explanation lifestyle program; handout of 
web based food diary, pedometer and activity diary.
Hand out of (cost) questionnaires
Blood sample
1 Outpatient 1 Setting targets and planning goals; evaluating baseline measures1,2 45-60
3 Outpatient 2 Evaluating targets1 45-60
5 Telephone 1 Evaluating targets1 15
7 Outpatient 3 Evaluating targets1 30
9 Telephone or e-mail 2 Evaluating targets1 15
12 Outpatient 4 Evaluating targets1,2
Handout of (cost) questionnaires
Blood sample
30
15 Telephone or e-mail 3 Evaluating targets1 15
18 Outpatient 5 Evaluating targets1 30
21 Telephone or e-mail 4 Evaluating targets1 15
24 Outpatient 6 Assessing targets and evaluation lifestyle program 1,2
Handout of (cost) questionnaires.
Blood sample
30
> 24 Outpatient Start subfertility treatment if applicable
52 (Cost) questionnaires
104 Cost questionnaire
1 Measuring weight, waist and hip circumference
2 Measuring blood pressure
when the couple has been subfertile for more than 3 years
(guideline NVOG). Fertility treatment can either be IUI,
IVF or ICSI, whatever is indicated according to the Dutch
guidelines (NVOG). When the Hunault model shows a
prognosis of more than 30% pregnancy chance in the
forthcoming year and the duration of subfertility is less
than three years, expectant management will be pro-
posed. In chronic anovulatory patients, ovulation induc-
tion will be started using clomiphene or gonadotropins
(Figure 1).
Questionnaires and Follow-Up
All participating women (the intervention and the control
arm) will complete several questionnaires: the SF-36
(measuring satisfaction) [41], the SQUASH list (for physi-
cal activity) [42] and the Dutch Eating Behaviour Ques-
tionnaire (DEBQ) for assessment of restrained, emotional
and external eating behaviour. [43] In addition, questions
will be asked on a women's food pattern (e.g. number and
timing of meals), important food components (e.g.
snacks, fruits, vegetables, sugar containing and alcoholic
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history of body weight (e.g. the duration of overweight
and weight fluctuations). Finally, each participant will
receive a questionnaire for details on associated direct
costs of professional care and on indirect costs like travel-
ling, sporting activity and productivity loss.
All mentioned questionnaires will be completed
through a secured web based application. In case a
patient decides not to use the web based application, she
will receive paper questionnaires. The questionnaires will
be completed at baseline, 12 weeks, 24 weeks and 52
weeks after randomisation and the questionnaire on costs
also at the end of the follow-up period. Finally, patients
who get pregnant during the period up to 24 months after
randomisation will receive a questionnaire in which they
can register their (self-reported) weight-gain during preg-
nancy. To assess gestational diabetes, an oral glucose tol-
erance test is advised for them at 28-30 weeks of
gestation.
A structured case record form (CRF) is used to register
reproductive outcome, fertility treatments as well as the
course and outcome of subsequent pregnancies (includ-
ing obstetrical interventions) for a period up to 24
months after randomisation.
Withdrawal of individual patients
Patients can leave the study at any time for any reason if
they wish to do so. Patients who drop out of the study will
be asked to provide the reason for dropping out. This rea-
son will be recorded and patients will be asked to provide
information regarding the primary outcome (a healthy
singleton born after at least 37 weeks of gestation after
vaginal delivery) within 24 months after randomisation.
In addition, they will be offered the possibility to continue
completing cost questionnaires for the remainder of the
study duration. Patients who drop out of the study will be
treated according to the local protocols and guidelines for
subfertility patients.
Safety Monitoring Board
An independent Safety Monitoring Board (SMB), blinded
for the study groups, will be installed to review complica-
tions related to fertility treatments, pregnancy, delivery
and neonatal outcome. This board will evaluate reported
complications after every 150 included patients and six
months and twelve months after the end of the inclusion
period (i.e. six times during the study). Furthermore,
every case of preeclampsia, eclampsia or HELLP syn-
drome will be reported immediately to the SMB. The
SMB will report its findings to the Medical Ethical Com-
mittee of the University Medical Center Groningen.
Outcome Measures
Main outcome measure
The primary endpoint will be a healthy singleton born
after at least 37 weeks of gestation after vaginal delivery.
Secondary study parameters/endpoints
Secondary outcome parameters are:
1. Pregnancy outcome and complications: miscarriage,
multiple pregnancies, gestational diabetes, pregnancy
induced hypertension, preeclampsia, HELLP syndrome,
Figure 1 Flowchart: Lifestyle study.
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Page 6 of 9prematurity (< 37 weeks), macrosomia (birth weight >
p90), induction of labour, prolonged duration of labour,
surgical delivery (caesarean section), assisted delivery,
peripartum increased blood loss (≥ 1000 ml).
2. Percentage of women needing fertility treatment in
both groups (OI, IUI, IVF, ICSI) and clinical and ongoing
pregnancy rates.
3. In case of IVF or ICSI: number and quality of
oocytes, embryos and cryopreserved embryos.
4. Perinatal outcome: weight for gestational age, apgar
scores, arterial pH, congenital anomalies, stillbirth, neo-
natal complications, and neonatal admission to a neona-
tal medium, high or intensive care unit.
5. Quality of life.
6. Additional parameters: weight changes, pre-preg-
nancy body weight, weight gain during pregnancy, waist
circumference, behaviour influencing weight, i.e. nutri-
tional habits and exercise pattern, blood pressure, glu-
cose/insulin ratio (HOMA), hormonal profile




Based on the literature, the cumulative rate of healthy sin-
gletons born after at least 37 weeks of gestation after vag-
inal delivery during a follow-up period of two years is set
at 45% for the control group[44]. We expect an improve-
ment of healthy singletons born after at least 37 weeks of
gestation after vaginal delivery from 45% to 60% in the
intervention group. To demonstrate this difference of
15% between the two groups, 272 women (alpha 0.05,
power 80%) are needed. To account for 5% loss to follow
up and 20% drop out, in total 570 women (285 women
per group) will be included.
To asses whether the groups are balanced, the study
population will be compared for baseline measurements
including female age, type of subfertility (primary or sec-
ondary), duration of subfertility, as well as sperm analysis
according to WHO standards, subfertility diagnosis and
initial BMI. Confounding factors, such as smoking and
intoxications, will be addressed in the analysis.
Univariate analysis and multivariate analysis
The primary analysis will be by intention to treat. The
cumulative rate of healthy singletons born after at least 37
weeks of gestation after vaginal delivery in both groups
will be compared using Kaplan-Meier analysis and the
Log-rank test. In this analysis, patients will be censured at
the time they discontinue or complete the study for other
reasons than getting pregnant. In addition, pregnancy
rates and 95% confidence intervals per group will be cal-
culated based on the Kaplan-Meier estimates at various
time points. Further analysis of delivery rates over time
will be performed using Cox-regression analysis with cor-
rection for the stratification variables (i.e. ovulatory sta-
tus and treatment centre) as well as for confounders.
These analyses will also be performed for spontaneous
and treatment-induced pregnancies separately. Explor-
atory subgroup analyses of the primary outcome will be
performed for women with a BMI below 35 kg/m2 versus
above 35 kg/m2 , as well as for anovulatory versus ovula-
tory women, for women with a waist-hip ratio of above
0.8 versus below or equal to 0.8 and for women who are
36 years or older versus younger than 36 years based on
tests of statistical interaction with effect of treatment
group.
The influence of HOMA, androgens, adipokines and
cytokines on pregnancy chances and recovery of ovula-
tions in anovulatory patients will be assessed using multi-
variate Cox-regression. Incidence of complications of
treatment and during pregnancy will be compared in
both groups using relative risks and 95% confidence
intervals. Quality of life will be analysed using repeated
measures analysis of variance. In the intervention group,
we will analyse and identify the motivational factors at
baseline which have a prognostic influence on the success
of the lifestyle intervention.
A per protocol analysis will also be performed, in which
patients who dropped out will be identified as non-com-
pliant. Information on the primary outcome (i.e. a healthy
singleton born after at least 37 weeks of gestation after
vaginal delivery) within 24 months after randomisation,
will be used whenever provided. Patients who drop out of
the lifestyle intervention arm will be analysed in the con-
ventional fertility care arm in this per protocol analysis.
Economic evaluation
The aim of the economic evaluation is to compare the
costs and health effects of the lifestyle program versus
conventional fertility care, by a cost-effectiveness analysis
with the proportion of healthy singletons born after at
least 37 weeks of gestation after vaginal delivery as the
primary outcome. These costs will be estimated in terms
of costs per additional healthy singleton born after at
least 37 weeks of gestation after vaginal delivery in a fol-
low up period of 24 months.
The economic evaluation will be performed from a
societal perspective. Direct medical and non-medical
costs (intervention costs, time and travel costs) as well as
indirect non-medical costs (productivity losses) will be
taken into account.
The time horizon will be from randomisation to the
end of follow-up. Resource use will be recorded as indi-
vidual patient data in the CRF, with additional informa-
tion from the cost questionnaires. Resource use will be
valued according to Dutch guidelines. Intervention costs
will be determined based on actual resource use obtained
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materials, equipment, housing and overhead. Productiv-
ity loss will be valued by the friction cost method accord-
ing to Dutch guidelines [45]. Costs of pregnancy and
delivery will be calculated based on data from the litera-
ture [46].
Detailed information on maternal complications will be
obtained from the patients medical files. Six weeks after
the expected day of delivery all women will be contacted
by telephone to obtain information about the delivery
and the health of their child. If the child has been hospita-
lised, the responsible paediatrician will be contacted for
further information.
Scenario analysis will be performed to model cost-
effectiveness beyond the time horizon of the study. For
longer term analyses, costs and effects will be discounted
at commonly accepted rates. Sensitivity analysis will be
performed on costs, pregnancy rates in the two groups
and the valuation of different outcomes (no child, handi-
capped child, twin, healthy child, obstetric complica-
tions). Uncertainty surrounding cost-effectiveness
estimates will be explored by bootstrapping.
Ethical Considerations
The study is conducted according to the principles of the
Declaration of Helsinki. The study protocol has been
approved by the Medical Ethical Committee of the Uni-
versity Medical Centre Groningen.
The protocol is registered in the Dutch clinical trial
register number NTR1530.
Discussion
Specialists working in the field of reproductive medicine
are frequently confronted with overweight and obese
subfertile women. It is assumed that their pregnancy
chances are reduced, and that they might benefit from
weight reduction. In addition, weight reduction might
lead to less pregnancy complications and consequently to
better pregnancy outcome for mother and child. There-
fore, BMI limits have been suggested for women under-
going fertility treatment, both with respect to patient's
safety as well as treatment efficacy [15,31]. However, for
most overweight and obese women weight reduction is
hard to achieve and up till now, well powered studies
addressing the issue of cost effectiveness of lifestyle inter-
vention aiming at weight reduction in overweight and
obese women with subfertility are lacking.
The present lifestyle study is the first large multicentre
randomised controlled trial in which the costs and effects
of a six-month during structured lifestyle program will be
compared to conventional fertility care in overweight and
obese subfertile women. The results of the study, which
are expected in 2014, will help to make evidence-based
guidelines for treatment in this patient group.
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